Antithrombotic therapy in 2017: Advances in atherosclerosis, atrial fibrillation, and valvular disease

Nature Reviews Cardiology

Volumn 15, Issue 2, 2018, Pages 71-72

  Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; HEMOGLOBIN; RIVAROXABAN; TICAGRELOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ALL CAUSE MORTALITY; AORTIC STENOSIS; AORTIC THROMBOSIS; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SECONDARY PREVENTION; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VALVULAR HEART DISEASE; BLEEDING; BLOOD; BLOOD CLOTTING; CARDIOLOGY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECT; HEART VALVE REPLACEMENT; MASS COMMUNICATION; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME; TRENDS;

ANTICOAGULANTS; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CARDIOLOGY; DIFFUSION OF INNOVATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 85040807198     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.212     Document Type: Review

References (10)

1. Bosch, J. et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can. J. Cardiol. 33, 1027-1035 (2017).
2. Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319-1330 (2017).
3. Connolly, S. J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32458-3 (2017).
4. Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32409-1 (2017).
5. Cannon, C. P. et al. Design and rationale of the RE - DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin. Cardiol. 39, 555-564 (2016).
6. Cannon, C. P. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 377, 1513-1524 (2017).
7. Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389, 1025-1034 (2017).
8. Makkar, R. R. et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N. Engl. J. Med. 373, 2015-2024 (2015).
9. Mangione, F. M. et al. Leaflet thrombosis in surgically explanted or post-mortem TAVR valves. JACC Cardiovasc. Imaging 10, 82-85 (2017).
10. Chakravarty, T. et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 389, 2383-2392 (2017).